ACADIA Pharmaceuticals, Inc. (NASDAQ:ACAD)

CAPS Rating: 2 out of 5

The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders.

Results 1 - 20 of 48 : 1 2 3 Next »

Recs

0
Member Avatar OklaBoston (66.59) Submitted: 4/23/2016 11:24:53 PM : Underperform Start Price: $33.94 ACAD Score: +3.91

Deteriorating technicals and dreadful valuations. Only a matter of time until it falls below $10.00, IMO.

Recs

0
Member Avatar horsetowater (< 20) Submitted: 3/28/2016 1:58:53 PM : Underperform Start Price: $24.65 ACAD Score: -29.79

Not a prayer in the 3-29-2016 FDA AdCom...

Recs

0
Member Avatar gcaderas (71.82) Submitted: 3/11/2016 7:11:33 AM : Underperform Start Price: $19.48 ACAD Score: -63.29

Qtr (03/16) Qtr (06/16) FY (12/16) FY (12/17)
Average Estimate $-0.40 $-0.45 $-1.24 $-1.02
Number of Analysts 5 3 7 4
High Estimate $-0.35 $-0.42 $0.57 $-0.54
Low Estimate $-0.44 $-0.47 $-1.78 $-1.55
Prior Year $-0.40 $-0.39 $-1.63 $-1.24
Growth Rate (Year over Year) 0.50% -15.38% 23.93% 17.34%

Recs

0
Member Avatar 78taxs (< 20) Submitted: 1/31/2016 3:53:25 AM : Outperform Start Price: $20.80 ACAD Score: +47.98

This drug is need it will soon be a go it did go on for a long time to get things right and they are there.

Recs

0
Member Avatar ZekelHealthcare (< 20) Submitted: 1/6/2016 12:35:51 PM : Outperform Start Price: $29.82 ACAD Score: +4.91

Healthcare up tick

Recs

0
Member Avatar 1russianguy (46.23) Submitted: 8/20/2015 3:29:53 PM : Outperform Start Price: $34.87 ACAD Score: -9.65

Playing for a bounce from a correction.

Recs

0
Member Avatar TMFTypeoh (77.56) Submitted: 6/24/2015 11:57:16 AM : Outperform Start Price: $42.96 ACAD Score: -22.49

Winner with a good looking pipeline.

Recs

0
Member Avatar NuclearSteve (66.70) Submitted: 4/7/2015 12:54:02 PM : Outperform Start Price: $33.41 ACAD Score: -2.33

It is time to own it again after they got shellacked for missing the NDA a second time.

Recs

1
Member Avatar drugtrader (90.47) Submitted: 2/27/2015 8:28:05 PM : Outperform Start Price: $32.41 ACAD Score: -1.48

This one could be really undervalued and likely hit $100 someday.

Great drug!

Recs

1
Member Avatar evanation (< 20) Submitted: 2/27/2015 5:49:21 PM : Outperform Start Price: $38.25 ACAD Score: -13.44

This is a speculative biotech, but is close to getting their first drug out.

Recs

0
Member Avatar craze191st (51.03) Submitted: 10/17/2014 2:35:21 PM : Outperform Start Price: $25.83 ACAD Score: +15.43

Primavanserin is sure to be a hit.

Recs

0
Member Avatar sam5454 (< 20) Submitted: 6/26/2014 7:25:26 PM : Outperform Start Price: $22.65 ACAD Score: +36.78

FDA approval is almost certain. A buyer will appear.

Recs

0
Member Avatar molmaemo (< 20) Submitted: 4/22/2014 11:23:26 AM : Outperform Start Price: $21.01 ACAD Score: +44.02

Every neighborhood block has a home for Alzheimer's patients. WE NEED TO MAKE THIS WORK. These diseases are overwhelming health care!

Recs

0
Member Avatar 2win (< 20) Submitted: 1/11/2014 12:36:28 PM : Outperform Start Price: $23.94 ACAD Score: +22.61

rebuying lower

Recs

0
Member Avatar pcguy (< 20) Submitted: 11/23/2013 2:54:50 AM : Underperform Start Price: $22.34 ACAD Score: -30.67

Catalysts too far out. Stock overbought.

Recs

0
Member Avatar SqwiiTrader (< 20) Submitted: 11/9/2013 6:11:31 PM : Underperform Start Price: $21.78 ACAD Score: -31.81

top hs pattern

Recs

0
Member Avatar stardog900 (< 20) Submitted: 7/27/2013 2:08:23 PM : Outperform Start Price: $18.51 ACAD Score: +52.18

If trials are successful, as is anticipated, this stock should outperform the S&P 500 greatly over the next year or two. Potential for large increase in value long term.

Recs

0
Member Avatar TheStockDoctor (< 20) Submitted: 6/11/2013 7:14:01 AM : Outperform Start Price: $19.57 ACAD Score: +38.70

Multiple new compounds fill an open void. Little price competition will protect profit margins.

Recs

0
Member Avatar TMFBiologyFool (91.92) Submitted: 11/27/2012 4:18:10 PM : Underperform Start Price: $4.92 ACAD Score: -508.87

No catalyst for awhile. And second phase 3 isn't a sure thing. Placebo effect is hard to beat twice.

Recs

0
Member Avatar BioPharmacist (< 20) Submitted: 11/24/2012 5:00:23 PM : Outperform Start Price: $2.23 ACAD Score: +1,301.73

Good Phase 3 coming

Results 1 - 20 of 48 : 1 2 3 Next »

Featured Broker Partners